Richard Buller Sells 3,000 Shares of Celcuity (NASDAQ:CELC) Stock

Celcuity, Inc. (NASDAQ:CELC) Director Richard Buller sold 3,000 shares of the business’s stock in a transaction on Tuesday, March 31st. The shares were sold at an average price of $110.27, for a total transaction of $330,810.00. Following the transaction, the director directly owned 6,760 shares in the company, valued at approximately $745,425.20. The trade was a 30.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Celcuity Trading Down 0.3%

NASDAQ CELC traded down $0.30 during trading on Thursday, hitting $112.63. The company had a trading volume of 501,390 shares, compared to its average volume of 725,079. The company’s fifty day moving average is $109.81 and its 200-day moving average is $92.12. Celcuity, Inc. has a one year low of $7.57 and a one year high of $120.32. The company has a current ratio of 10.55, a quick ratio of 10.55 and a debt-to-equity ratio of 3.20. The company has a market cap of $5.44 billion, a price-to-earnings ratio of -29.72 and a beta of 0.41.

Celcuity (NASDAQ:CELC) last announced its earnings results on Wednesday, March 25th. The company reported ($0.97) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.06) by $0.09. On average, sell-side analysts predict that Celcuity, Inc. will post -2.62 earnings per share for the current year.

Analyst Ratings Changes

CELC has been the topic of a number of research analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $122.00 target price on shares of Celcuity in a report on Thursday, March 26th. Wall Street Zen upgraded Celcuity from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Wolfe Research restated an “outperform” rating and set a $110.00 price target on shares of Celcuity in a research report on Thursday, March 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Celcuity in a report on Wednesday, January 21st. Finally, Wells Fargo & Company assumed coverage on Celcuity in a research report on Friday, December 12th. They set an “overweight” rating and a $126.00 price objective for the company. Eight investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $109.88.

Hedge Funds Weigh In On Celcuity

Institutional investors and hedge funds have recently made changes to their positions in the business. Creative Planning purchased a new position in shares of Celcuity during the second quarter valued at approximately $177,000. Intech Investment Management LLC grew its stake in shares of Celcuity by 5.2% in the 2nd quarter. Intech Investment Management LLC now owns 14,855 shares of the company’s stock worth $198,000 after buying an additional 734 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Celcuity by 1.2% in the 2nd quarter. Rhumbline Advisers now owns 42,697 shares of the company’s stock worth $570,000 after buying an additional 503 shares during the last quarter. XTX Topco Ltd bought a new position in Celcuity during the 2nd quarter valued at approximately $169,000. Finally, Saturn V Capital Management LP increased its position in Celcuity by 8.4% during the 2nd quarter. Saturn V Capital Management LP now owns 1,185,520 shares of the company’s stock valued at $15,827,000 after buying an additional 91,843 shares in the last quarter. Institutional investors own 63.33% of the company’s stock.

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.